Characterizing the invasion of different breast cancer cell lines with distinct E-cadherin status in 3D using a microfluidic system.


Journal

Biomedical microdevices
ISSN: 1572-8781
Titre abrégé: Biomed Microdevices
Pays: United States
ID NLM: 100887374

Informations de publication

Date de publication:
23 11 2019
Historique:
entrez: 25 11 2019
pubmed: 25 11 2019
medline: 9 4 2020
Statut: epublish

Résumé

E-cadherin is a cell-cell adhesion protein that plays a prominent role in cancer invasion. Inactivation of E-cadherin in breast cancer can arise from gene promoter hypermethylation or genetic mutation. Depending on their E-cadherin status, breast cancer cells adopt different morphologies with distinct invasion modes. The tumor microenvironment (TME) can also affect the cell morphology and invasion mode. In this paper, we used a previously developed microfluidic system to quantify the three-dimensional invasion of breast cancer cells with different E-cadherin status, namely MCF-7, CAMA-1 and MDA-MB-231 with wild type, mutated and promoter hypermethylated E-cadherin, respectively. The cells migrated into a stable and reproducible microfibrous polycaprolactone mesh in the chip under a programmed stable chemotactic gradient. We observed that the MDA-MB-231 cells invaded the most, as single cells. MCF-7 cells collectively invaded into the matrix more than CAMA-1 cells, maintaining their E-cadherin expression. The CAMA-1 cells exhibited multicellular multifocal infiltration into the matrix. These results are consistent with what is seen in vivo in the cancer biology literature. In addition, comparison between complete serum and serum gradient conditions showed that the MDA-MB-231 cells invaded more under the serum gradient after one day, however this behavior was inverted after 3 days. The results showcase that the microfluidic system can be used to quantitatively assess the invasion behavior of cancer cells with different E-cadherin expression, for a longer period than conventional invasion models. In the future, it can be used to quantitatively investigate effects of matrix structure and cell treatments on cancer invasion.

Identifiants

pubmed: 31760501
doi: 10.1007/s10544-019-0450-5
pii: 10.1007/s10544-019-0450-5
pmc: PMC6875428
doi:

Substances chimiques

Cadherins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101

Références

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11115-20
pubmed: 21690404
J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):11-21
pubmed: 17197171
Cancer Cell. 2014 Aug 11;26(2):163-76
pubmed: 25043604
Biomed Microdevices. 2017 Oct 17;19(4):92
pubmed: 29038872
Cancer Res. 1995 Nov 15;55(22):5195-9
pubmed: 7585573
Mol Cancer Res. 2007 Feb;5(2):195-201
pubmed: 17314276
Nat Rev Cancer. 2011 Jul 22;11(8):573-87
pubmed: 21779009
Biochim Biophys Acta. 2012 Aug;1826(1):23-31
pubmed: 22440943
Cell Mol Life Sci. 2013 Apr;70(8):1335-56
pubmed: 22926411
Clin Exp Metastasis. 2017 Oct;34(6-7):421-429
pubmed: 28894989
Breast Cancer Res Treat. 2010 Jul;122(1):125-33
pubmed: 19763817
Mol Oncol. 2007 Jun;1(1):84-96
pubmed: 18516279
Biomacromolecules. 2006 Oct;7(10):2796-805
pubmed: 17025355
Breast Cancer Res. 2013 Apr 19;15(2):R33
pubmed: 23601657
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Br J Cancer. 2006 Mar 13;94(5):661-71
pubmed: 16495925
Intravital. 2013 Apr 1;2(2):e25294
pubmed: 25013744
Dis Model Mech. 2018 Mar 16;11(3):
pubmed: 29555848
Cancer Res. 2001 Jan 1;61(1):278-84
pubmed: 11196175
Nat Rev Mol Cell Biol. 2009 Jul;10(7):445-57
pubmed: 19546857
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
pubmed: 20457567
Cell. 2011 Nov 23;147(5):992-1009
pubmed: 22118458
J Vis Exp. 2014 Jun 01;(88):
pubmed: 24962652
Lab Chip. 2013 Jul 7;13(13):2484-99
pubmed: 23712326
Breast Cancer Res Treat. 2012 Nov;136(2):365-77
pubmed: 23053649
Pathol Res Pract. 2016 Jul;212(7):583-97
pubmed: 27233940
Curr Opin Cell Biol. 2014 Oct;30:99-111
pubmed: 25137487
Breast Cancer Res Treat. 2013 Feb;138(1):47-57
pubmed: 23338761
Sci Rep. 2016 Sep 28;6:34094
pubmed: 27678304

Auteurs

H Eslami Amirabadi (H)

Microsystems group, Department of Mechanical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands.
Healthy living division, TNO, Zeist, the Netherlands.
Institute for Pharmeceutical Sciences, Department of Pharmacology, Utrecht University, Utrecht, the Netherlands.

M Tuerlings (M)

Microsystems group, Department of Mechanical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands.
Orthopaedic Biomechanics group, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands.

A Hollestelle (A)

Department of Medical oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

S SahebAli (S)

Microsystems group, Department of Mechanical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands.

R Luttge (R)

Microsystems group, Department of Mechanical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands.

C C van Donkelaar (CC)

Orthopaedic Biomechanics group, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands.

J W M Martens (JWM)

Department of Medical oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

J M J den Toonder (JMJ)

Microsystems group, Department of Mechanical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Groene Loper 15, 5612AZ, Eindhoven, the Netherlands. j.m.j.d.toonder@tue.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH